[go: up one dir, main page]

JO3705B1 - إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية - Google Patents

إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية

Info

Publication number
JO3705B1
JO3705B1 JOP/2015/0287A JOP20150287A JO3705B1 JO 3705 B1 JO3705 B1 JO 3705B1 JO P20150287 A JOP20150287 A JO P20150287A JO 3705 B1 JO3705 B1 JO 3705B1
Authority
JO
Jordan
Prior art keywords
medicaments
processes
preparation
production
endometriosis
Prior art date
Application number
JOP/2015/0287A
Other languages
English (en)
Inventor
Reinhard Nubbemeyer Dr
Martin Lange Dr
Alexandra Rausch Dr
Holger Steuber Dr
Friedrich Christian
Ulf B?Mer Dr
Andreas Sutter Dr
Hauff Peter
Nicole Schmidt Dr
Holger Siebeneicher Dr
Judith Gunther Dr
Christian Stegmann Dr
Ulrich Bothe Dr
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of JO3705B1 publication Critical patent/JO3705B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

يتعلق الطلب الحالي بمركبات indazoles مستبدلة جديدة، بعمليات لتحضيرها، باستخدامها بمفردها أو في اتحاد لمعالجة /أو الوقاية من أمراض، وباستخدامها في إنتاج أدوية لمعالجة و/أو الوقاية من أمراض، خصوصا معالجة و/أو الوقاية من الانتباذ البطاني الرحمي والألم المصاحب للانتباذ البطاني الرحمي والأعراض المصاحبة للانتباذ البطاني الرحمي الأخرى مثل عسر الطمث، عسر الجماع، عسر التبول وعسر التغوط، الليمفوما، التهاب المفاصل الروماتويدي، التهاب المفاصل الفقارية (خصوصا التهاب المفاصل الفقارية الصدفي ومرض Bekhterev)، الذئبة الحمامية النظامية، التصلب المتعدد، التحلل البقعي، COPD (مرض الإعاقة الرئوية المزمنة (chronic obstructive pulmonary disease))، النقرس، اضطرابات الكبد الدهني، مقاومة الإنسولين، الاضطرابات الورمية والصدفية.
JOP/2015/0287A 2014-11-26 2015-11-23 إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية JO3705B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14195032 2014-11-26

Publications (1)

Publication Number Publication Date
JO3705B1 true JO3705B1 (ar) 2021-01-31

Family

ID=51982455

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0287A JO3705B1 (ar) 2014-11-26 2015-11-23 إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية

Country Status (42)

Country Link
US (6) US10308634B2 (ar)
EP (3) EP4260909A3 (ar)
JP (1) JP6496823B2 (ar)
KR (1) KR102083857B1 (ar)
CN (2) CN110305109B (ar)
AR (1) AR102827A1 (ar)
AU (2) AU2015352603B2 (ar)
BR (2) BR122021002613B1 (ar)
CA (1) CA2968614C (ar)
CL (1) CL2017001364A1 (ar)
CO (1) CO2017005374A2 (ar)
CR (1) CR20170220A (ar)
CU (1) CU24448B1 (ar)
CY (1) CY1123815T1 (ar)
DK (2) DK3674298T3 (ar)
DO (1) DOP2017000127A (ar)
EA (1) EA032509B1 (ar)
EC (1) ECSP17032530A (ar)
ES (2) ES2976932T3 (ar)
FI (1) FI3674298T3 (ar)
HR (2) HRP20240414T1 (ar)
HU (2) HUE049341T2 (ar)
IL (3) IL252185B (ar)
JO (1) JO3705B1 (ar)
LT (2) LT3674298T (ar)
MA (1) MA41011B1 (ar)
ME (1) ME03745B (ar)
MX (2) MX2020010623A (ar)
NI (1) NI201700063A (ar)
NZ (1) NZ732126A (ar)
PE (1) PE20171376A1 (ar)
PH (1) PH12017500972A1 (ar)
PL (2) PL3224254T3 (ar)
PT (2) PT3224254T (ar)
RS (2) RS60284B1 (ar)
SG (3) SG10201903475TA (ar)
SI (2) SI3674298T1 (ar)
TN (1) TN2017000226A1 (ar)
TW (2) TWI689502B (ar)
UA (2) UA120948C2 (ar)
UY (1) UY36411A (ar)
WO (1) WO2016083433A1 (ar)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015205348A1 (en) 2014-01-10 2016-07-28 Aurigene Discovery Technologies Limited Indazole compounds as IRAK4 inhibitors
AU2015205374B2 (en) 2014-01-13 2018-08-23 Aurigene Oncology Limited Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
JO3705B1 (ar) * 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
EP3195865A1 (de) * 2016-01-25 2017-07-26 Bayer Pharma Aktiengesellschaft Kombinationen von irak4 inhibitoren und btk inhibitoren
UY36660A (es) * 2015-04-30 2016-11-30 Bayer Pharma AG Combinaciones de inhibidores de irak4
US10435396B2 (en) 2016-03-03 2019-10-08 Bayer Pharma Aktiegesellschaft 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
EP3219329A1 (en) * 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
CN109071491B (zh) * 2016-04-29 2020-08-21 拜耳医药股份有限公司 吲唑的合成
EA035867B1 (ru) * 2016-04-29 2020-08-24 Байер Фарма Акциенгезельшафт Синтез индазолов
WO2017186703A1 (en) * 2016-04-29 2017-11-02 Bayer Pharma Aktiengesellschaft Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
DK3464266T3 (da) 2016-06-01 2021-11-22 Bayer Animal Health Gmbh Substituerede indazoler, der er anvendelige til behandling og forebyggelse af allergiske og/eller inflammatoriske sygdomme hos dyr
CN109152771B (zh) * 2016-06-01 2022-07-19 拜耳医药股份有限公司 2-取代的吲唑用于治疗和预防自身免疫疾病的用途
CN115819417A (zh) 2016-09-09 2023-03-21 因赛特公司 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
TW201811799A (zh) 2016-09-09 2018-04-01 美商英塞特公司 吡唑并嘧啶化合物及其用途
WO2018060072A1 (de) 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
FI3600270T3 (fi) 2017-03-31 2023-07-20 Aurigene Oncology Ltd Yhdisteitä ja koostumuksia hematologisten häiriöiden hoitoon
WO2018200786A1 (en) * 2017-04-26 2018-11-01 Yale University Compositions and methods for treating vitiligo
US10508105B2 (en) 2017-08-16 2019-12-17 Vanderbilt University Indazole compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2019051199A1 (en) 2017-09-08 2019-03-14 Incyte Corporation 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
DK3755703T3 (da) 2018-02-20 2022-06-27 Incyte Corp N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
CN112638430B (zh) 2018-06-27 2023-05-16 豪夫迈·罗氏有限公司 放射性标记的大麻素受体2配体
CN112119068A (zh) 2018-06-27 2020-12-22 豪夫迈·罗氏有限公司 作为大麻素受体2的抑制剂的新型氮杂环丁烷-取代的吡啶和吡嗪化合物
KR20210028202A (ko) 2018-06-27 2021-03-11 에프. 호프만-라 로슈 아게 칸나비노이드 수용체 2의 억제제로서 신규한 피리딘 및 피라진 화합물
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
US11897863B2 (en) 2018-08-17 2024-02-13 Zhejiang Hisun Pharmaceutical Co., Ltd. Indazole amine derivative, preparation method therefor and medical use thereof
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
US11111247B2 (en) 2018-09-25 2021-09-07 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
CN111362920B (zh) * 2018-12-25 2024-06-07 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物
WO2020135513A1 (zh) * 2018-12-25 2020-07-02 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物
CN111499612B (zh) * 2019-01-30 2022-12-30 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物及其制备方法和用途
CN111560012B (zh) * 2019-02-14 2023-06-23 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物
CN111793064B (zh) * 2019-04-02 2023-06-23 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物及其制备方法和用途
CN113825755B (zh) * 2019-06-26 2023-04-25 南京明德新药研发有限公司 作为irak4抑制剂的咪唑并吡啶类化合物
UY38765A (es) * 2019-06-27 2021-01-29 Biogen Ma Inc Derivados de 2h-indazol y su uso en el tratamiento de enfermedades
JP2022540200A (ja) 2019-07-11 2022-09-14 エスケイプ・バイオ・インコーポレイテッド Ｌｒｒｋ２阻害剤としてのインダゾールおよびアザインダゾール
CR20220097A (es) 2019-08-06 2022-06-01 Incyte Corp Formas sólidas de un inhibidor de hpk1
CN114391013B (zh) * 2019-09-24 2024-01-26 上海美悦生物科技发展有限公司 一种irak抑制剂及其制备方法和用途
CN111072634B (zh) * 2020-01-03 2022-07-22 中国医科大学 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用
CN113521079A (zh) * 2020-04-20 2021-10-22 上海领泰生物医药科技有限公司 Irak4抑制剂在治疗ali/ards中的应用
US11866405B2 (en) 2020-12-10 2024-01-09 Astrazeneca Ab Substituted indazoles as IRAK4 inhibitors
BR112023020669A2 (pt) 2021-04-08 2023-12-12 Curis Inc Terapias de combinação para o tratamento de câncer
CN113278017B (zh) * 2021-05-27 2023-03-28 上海应用技术大学 取代吲唑类化合物、制备方法、应用和包含其的组合物
CN113402499B (zh) 2021-06-21 2022-05-13 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途
EP4366834A1 (en) * 2021-07-07 2024-05-15 Biogen MA Inc. Compounds for targeting degradation of irak4 proteins
WO2023098857A1 (zh) * 2021-12-03 2023-06-08 武汉人福创新药物研发中心有限公司 Irak4抑制剂及其用途
WO2024108010A1 (en) * 2022-11-17 2024-05-23 Bayer Animal Health Gmbh Methods and compositions for control of pain and inflammation
CN116120283B (zh) * 2022-12-13 2025-01-28 药康众拓(北京)医药科技有限公司 一种氘代啶酰胺类irak-4抑制剂药物及用途
WO2025003988A1 (ko) * 2023-06-29 2025-01-02 동화약품주식회사 신규한 카르복사마이드 유도체 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246606B1 (es) 2002-07-23 2007-06-01 Izar Construcciones Navales S.A. Unidad semi-sumergible auto-propulsada para transporte y engorde de peces vivos.
EP1594841A1 (de) * 2002-07-31 2005-11-16 Schering Aktiengesellschaft Vegfr-2 und vegfr-3 inhibitorische anthranylamidpyridine
EP1646608B1 (en) 2003-06-25 2011-03-02 JE IL Pharmaceutical Co., Ltd. Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them
WO2005082866A2 (en) 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
WO2006061715A2 (en) 2004-12-08 2006-06-15 Warner-Lambert Company Llc Methylene inhibitors of matrix metalloproteinase
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
GB0518671D0 (en) * 2005-09-13 2005-10-19 Novartis Ag Organic compounds
GT200600411A (es) * 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
US7745477B2 (en) 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
US20100048660A1 (en) 2006-02-10 2010-02-25 Graham Michael Wynne Treatment of duchenne muscular dystrophy
TWI435863B (zh) 2006-03-20 2014-05-01 Nihon Nohyaku Co Ltd Ｎ-２-（雜）芳基乙基甲醯胺衍生物及含該衍生物之蟲害防治劑
US7879887B2 (en) 2006-06-29 2011-02-01 Nissan Chemical Industries, Ltd. α-amino acid derivatives and medicaments containing the same as an active ingredient
JP2010502717A (ja) * 2006-09-07 2010-01-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド インターロイキン１受容体関連キナーゼの調節物質
FR2917735B1 (fr) 2007-06-21 2009-09-04 Sanofi Aventis Sa Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
US20090069288A1 (en) * 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
JP2013512878A (ja) * 2009-12-03 2013-04-18 グラクソ グループ リミテッド 新規化合物
WO2011153588A1 (en) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
US20140113898A1 (en) 2010-11-08 2014-04-24 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
US9073892B2 (en) * 2010-12-20 2015-07-07 Merck Serono S.A. Indazolyl triazol derivatives
BR112013020270A2 (pt) 2011-02-10 2016-07-12 Syngenta Participations Ag derivados de pirazol microbicidas
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
AU2012217616B2 (en) 2011-02-18 2017-03-02 Vertex Pharmaceuticals Incorporated Chroman - spirocyclic piperidine amides as modulators of ion channels
WO2013106254A1 (en) 2012-01-11 2013-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
CN104507950B (zh) 2012-05-21 2017-03-22 拜耳医药股份有限公司 噻吩并嘧啶
JP2015002717A (ja) 2013-06-21 2015-01-08 住友ベークライト株式会社 蓋付き容器
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
AU2015205348A1 (en) 2014-01-10 2016-07-28 Aurigene Discovery Technologies Limited Indazole compounds as IRAK4 inhibitors
WO2015193846A1 (en) 2014-06-20 2015-12-23 Aurigene Discovery Technologies Limited Substituted indazole compounds as irak4 inhibitors
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
UY36660A (es) 2015-04-30 2016-11-30 Bayer Pharma AG Combinaciones de inhibidores de irak4
MX2018000512A (es) 2015-07-15 2018-04-13 Aurigene Discovery Tech Ltd Compuestos de indazaol y azaindazol como inhibidores de la cinasa 4 asociada al receptor de interlucina 1 (irak-4).
US10435396B2 (en) 2016-03-03 2019-10-08 Bayer Pharma Aktiegesellschaft 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
WO2017186703A1 (en) 2016-04-29 2017-11-02 Bayer Pharma Aktiengesellschaft Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
CN109071491B (zh) 2016-04-29 2020-08-21 拜耳医药股份有限公司 吲唑的合成
CN109152771B (zh) 2016-06-01 2022-07-19 拜耳医药股份有限公司 2-取代的吲唑用于治疗和预防自身免疫疾病的用途
DK3464266T3 (da) 2016-06-01 2021-11-22 Bayer Animal Health Gmbh Substituerede indazoler, der er anvendelige til behandling og forebyggelse af allergiske og/eller inflammatoriske sygdomme hos dyr

Also Published As

Publication number Publication date
CY1123815T1 (el) 2022-03-24
CN110305109B (zh) 2022-04-08
HRP20200974T1 (hr) 2020-10-02
LT3224254T (lt) 2020-06-10
IL252185A0 (en) 2017-07-31
KR102083857B1 (ko) 2020-03-03
CA2968614A1 (en) 2016-06-02
WO2016083433A1 (de) 2016-06-02
US20210053941A1 (en) 2021-02-25
LT3674298T (lt) 2024-04-10
PL3224254T3 (pl) 2020-09-21
BR112017011005A2 (pt) 2019-05-14
US10793545B2 (en) 2020-10-06
EA201791137A1 (ru) 2017-11-30
IL252185B (en) 2019-10-31
FI3674298T3 (fi) 2024-04-17
EP3224254A1 (de) 2017-10-04
BR112017011005B1 (pt) 2023-03-14
CO2017005374A2 (es) 2017-08-31
PT3674298T (pt) 2024-04-01
CN107406416B (zh) 2020-04-21
TN2017000226A1 (en) 2018-10-19
CA2968614C (en) 2019-10-29
IL267537B (en) 2020-07-30
MX2017006910A (es) 2017-08-15
US20250034111A1 (en) 2025-01-30
TWI717061B (zh) 2021-01-21
AR102827A1 (es) 2017-03-29
US20230174508A1 (en) 2023-06-08
EA032509B1 (ru) 2019-06-28
HUE049341T2 (hu) 2020-09-28
AU2020200979B2 (en) 2021-01-07
ES2796285T3 (es) 2020-11-26
EP4260909A3 (de) 2024-03-20
CN110305109A (zh) 2019-10-08
NZ732126A (en) 2018-09-28
UA123813C2 (uk) 2021-06-02
DK3674298T3 (da) 2024-04-08
TW201629037A (zh) 2016-08-16
EP3674298B1 (de) 2024-01-10
UA120948C2 (uk) 2020-03-10
MX2020010623A (es) 2022-02-16
SI3224254T1 (sl) 2020-07-31
ME03745B (me) 2021-04-20
SG11201704092YA (en) 2017-06-29
IL267537A (en) 2019-08-29
RS60284B1 (sr) 2020-06-30
JP6496823B2 (ja) 2019-04-10
ECSP17032530A (es) 2017-06-30
DOP2017000127A (es) 2017-07-31
KR20170085590A (ko) 2017-07-24
NI201700063A (es) 2017-07-17
DK3224254T3 (da) 2020-07-13
CN107406416A (zh) 2017-11-28
JP2017535585A (ja) 2017-11-30
US10308634B2 (en) 2019-06-04
EP3674298A1 (de) 2020-07-01
ES2976932T9 (es) 2024-09-05
SG10201903475TA (en) 2019-05-30
CL2017001364A1 (es) 2017-12-15
IL269444B (en) 2020-07-30
BR122021002613B1 (pt) 2023-04-11
IL269444A (en) 2019-11-28
HUE065938T2 (hu) 2024-06-28
PT3224254T (pt) 2020-06-17
HRP20240414T1 (hr) 2024-06-21
TW202002973A (zh) 2020-01-16
SG10201903474PA (en) 2019-05-30
MA41011B1 (fr) 2020-08-31
PE20171376A1 (es) 2017-09-15
PH12017500972A1 (en) 2017-12-18
RS65327B1 (sr) 2024-04-30
CR20170220A (es) 2017-10-31
EP3674298B9 (de) 2024-06-19
US20220388982A1 (en) 2022-12-08
US20170349570A1 (en) 2017-12-07
AU2015352603A1 (en) 2017-06-01
AU2015352603B2 (en) 2020-04-02
CU20170073A7 (es) 2017-10-05
ES2976932T3 (es) 2024-08-13
SI3674298T1 (sl) 2024-05-31
EP4260909A2 (de) 2023-10-18
CU24448B1 (es) 2019-10-04
TWI689502B (zh) 2020-04-01
UY36411A (es) 2016-06-30
PL3674298T3 (pl) 2024-06-24
AU2020200979A1 (en) 2020-02-27
US12006303B2 (en) 2024-06-11
US12006304B2 (en) 2024-06-11
EP3224254B1 (de) 2020-04-15
US20190233395A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
JO3705B1 (ar) إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12018500586B1 (en) Farnesoid x receptor agonists and uses thereof
UY37142A (es) Nuevos indazoles 2-sustituidos, procedimientos para su preparación, preparados farmacéuticos que los contienen,así como su uso para la preparación de medicamentos
ZA201908214B (en) Anti-bcma heavy chain-only antibodies
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
MX2018007704A (es) Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante.
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
MX2019006495A (es) Tratamiento de enfermedades neurologicas.
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
MX2017006483A (es) Compuestos aminopirazina con propiedades antagonistas a2a.
MX2021010666A (es) Moleculas de fusion derivadas de la toxina colix para suministro oral de una carga biologicamente activa.
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
PH12016500814A1 (en) Heteroaryl butanoic acid derivatives
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
MY193740A (en) "substituted 2,4 diamino-quinoline as new anticancer agents"
EP4406969A3 (en) Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
PH12018502278A1 (en) Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies
WO2016144706A3 (en) Autotaxin inhibitor compounds and uses thereof
PL409386A1 (pl) Preparaty peptydowe do zastosowania jako środek farmaceutyczny lub dodatek do żywności w zapobieganiu i leczeniu chorób neurodegeneracyjnych
WO2015150468A3 (en) Novel ifn beta protein analogs